Therapeutic Effects of Aldose Reductase Inhibitor on Diabetic Peripheral Neuropathy

李红,陈亚青,周筠,贺铭,雷涛,宋利格,张秀珍
DOI: https://doi.org/10.3321/j.issn:1006-6187.2007.11.009
2007-01-01
Abstract:Objective To investigate the effects of aldose reductase inhibitor on diabetic peripheral neuropathy(DPN).Methods 158 DPN patients were randomized to therapy group including 88 patients receiving Epalrestat and control group including 70 patients taking antihyperglycemic drugs only.Electromyography was taken and measurements of fasting blood glucose(FPG),postprandial blood sugar(PPG),glycosylated hemoglobin(HbA1c),endothelin(ET) were performed before and after treatment.Results The motor nerve conduction velocities(MNCV) of median nerve before and after medication were 40.8±5.6m/s and 46.5±4.1m/s respectively in therapy group,and 40.6±5.3m/s and 40.2±4.8m/s respectively in control group.In therapy group,the sensory nerve conduction velocities(SNCV) of median nerve before and after medication were 34.2±2.6m/s and 39.0±3.9m/s respectively,versus control group of 34.5±2.5m/s and 35.6±2.8m/s respectively.In therapy group,the motor nerve conduction velocities of peroneal nerve before and after medication were 36.1±2.3m/s and 39.4±2.2m/s versus control group of 36.3±2.6m/s and 36.6±3.1m/s respectively.In therapy group,the sensory nerve conduction velocities of peroneal nerve before and after medication were 34.1±1.6m/s and 39.4±2.2m/s,versus control group of 36.2±1.9m/s and 36.5±2.1m/s respectively.In therapy group before and after treatment,the levels of endothelin were 122.41±12.83pg/ml and 60.01±14.74pg/ml versus control group of 123.28±15.64pg/ml and 116.54±16.32pg/ml respectively.There were significant differences in the above parameters between pre-and post-treatmont and between groups of treatment and control(all P0.01).Conclusion Aldose reductase inhibitor could accelerate the nerve conduction velocity,and has a significant effect on DPN therapy.
What problem does this paper attempt to address?